(i) TREATY REQUIREMENT.—Any agreement to form a partnership under this section shall be formalized as a treaty subject to the advice and consent of the Senate.

SA 1740. Mr. LEAHY (for himself and Mr. TILLIS) submitted an amendment intended to be proposed by him to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place, insert the following:

SEC. _____. OWNERSHIP AND ASSIGNMENT OF PATENTS.

Section 261 of title 35, United States Code, is amended—

- (1) by striking the first undesignated paragraph and inserting the following:
 - "(a) IN GENERAL.-
- "(1) ATTRIBUTES OF PERSONAL PROPERTY.—Subject to the provisions of this title, patents shall have the attributes of personal property.
- "(2) REGISTER OF INTERESTS.—The Patent and Trademark Office shall—
- ``(A) maintain a register of interests in patents and applications for patents;
- "(B) record any document related thereto upon request;
- "(C) not later than 90 days after the date on which a patent, or any interest in a patent of not less than 10 percent (in the aggregate), is assigned to any foreign entity or person, require the recording of that assignment; and
- "(D) maintain a publicly accessible database that is digitally searchable by fields based on patent number, assignee, assignor, assignment date, and other criteria established by the Office.
- "(3) EFFECT OF FAILURE TO COMPLY.—No party may recover, for infringement of a patent in any litigation, any monetary damages for any period in which ownership with respect to the patent is not properly recorded in accordance with the requirements of this subsection.":
- (2) in the first undesignated paragraph following subsection (a), as so designated by paragraph (1) of this section, by striking "Applications" and inserting the following:
- "(b) APPLICATIONS.—Applications";
 (3) in the first undesignated paragraph following subsection (b), as so designated by paragraph (2) of this section, by striking "A certificate" and inserting the following:
- "(c) CERTIFICATE OF ACKNOWLEDGMENT.—A certificate"; and
- (4) in the first undesignated paragraph following subsection (c), as so designated by paragraph (3) of this section, by striking "An interest" and inserting the following:
 - "(d) Effect of Assignment.—An interest".

SA 1741. Mr. LEAHY (for himself and Mr. TILLIS) submitted an amendment intended to be proposed by him to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical sup-

ply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place, insert the following:

SEC. . PATENTS.

- (a) IN GENERAL.—Chapter 30 of title 35, United States Code, is amended—
- (1) in section 302, in the first sentence, by inserting "or on the basis of credible evidence that any such claim was obtained through fraud" after "section 301";
 - (2) in section 303—
 - (A) in subsection (a)—
- (i) in the first sentence, by inserting "or enforceability" after "patentability"; and
- (ii) in the second sentence, by inserting ", or a substantial new question of enforce-ability is raised by credible evidence of fraud," after "patents and publications"; and
- (B) in subsection (c), in the first sentence, by inserting "or enforceability" after "patentability":
- (3) in section 304, in the first sentence, by inserting "or enforceability" after "patentability"; and
 - (4) in section 307-
- (A) in the section heading, by inserting "unenforceability," after "unpatentability,"; and
- (B) in subsection (a), by inserting "or unenforceable" after "unpatentable".
- (b) TECHNICAL AND CONFORMING AMEND-MENT.—The table of sections for chapter 30 of title 35, United States Code, is amended by striking the item relating to section 307 and inserting the following:

"307. Certificate of patentability, unpatentability, unenforce-ability, and claim cancellation.".

SA 1742. Ms. SMITH (for herself and Mr. Cassidy) submitted an amendment intended to be proposed by her to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in title I of division F, insert the following:

SEC. 61___. ESSENTIAL GENERIC ANTIBIOTIC PROGRAM.

- (a) GRANT PROGRAM.—
- (1) ESTABLISHMENT.—Not later than 60 days after the date of enactment of this Act, the Secretary shall establish a program to provide grants to manufacturers of essential generic antibiotic drugs, or the active pharmaceutical ingredient or articles used as components of such drug, to support activities described in paragraph (3).
- (2) ELIGIBLE ENTITIES.—The Secretary shall award grants under this subsection to not more than 3 manufacturers of an essential generic antibiotic drug. Each such recipient shall be a manufacturer that—
- (A) has implemented and maintains an effective quality management system, under parts 210 and 211 of title 21, Code of Federal Regulations (or any successor regulations);
- (B) has a strong record of compliance with the requirements of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);
- (C) commits to using advanced manufacturing in its domestic manufacturing operations; and
- (D) has existing manufacturing facilities and operations in the United States.

- (3) USE OF FUNDS.—A recipient of a grant under this subsection may use such grant funds to—
- (A) with respect to manufacturing an essential generic antibiotic drug—
- (i) expand, upgrade, or recommission an existing manufacturing facility located in the United States; or
- (ii) construct a new manufacturing facility in the United States; and
- (B) manufacture essential generic antibiotic drugs using advanced manufacturing techniques.
- (b) USE OF FUNDS TO PURCHASE ESSENTIAL GENERIC ANTIBIOTIC DRUGS FOR STOCK-PILING.—The Secretary may use amounts appropriated under this section to purchase, store, stockpile, or disposition essential generic antibiotic drugs manufactured in the United States.
- (c) DEFINITIONS.—For purposes of this section:
- (1) ACTIVE PHARMACEUTICAL INGREDIENT.— The term "active pharmaceutical ingredient" has the meaning given such term in section 744A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j-41).
- (2) ADVANCED MANUFACTURING.—The term "advanced manufacturing" means an approach for the manufacturing of drugs that incorporates novel technology, or uses an established technique or technology in a new or innovative way, that enhances drug product quality or improves the manufacturing process.
- (3) ESSENTIAL GENERIC ANTIBIOTIC DRUG.—
 The term "essential generic antibiotic drug"
 means an antibacterial or antifungal drug
 approved by the Food and Drug Administration under section 505(j) of the Federal Food,
 Drug, and Cosmetic Act (21 U.S.C. 355(j)) that
 the Secretary determines to be medically
 necessary to have available at all times in an
 amount adequate to serve patient needs, including beta-lactams (including penicillin
 and cephalosporin derivatives) and non-beta
 lactams (including tetracycline and
 aminoglycoside derivatives).
- (4) SECRETARY.—The term "Secretary" means the Secretary of Health and Human Services.
- (5) UNITED STATES.—The term "United States" means the 50 States, the District of Columbia, territories, and Tribal lands.
- (d) FUNDING.—For purposes of carrying out this section (other than subsection (e)), there is appropriated, out of amounts in the Treasury not otherwise appropriated, \$500,000,000 for fiscal year 2021, to remain available through September 30, 2023.
 - (e) STUDY AND REPORT.—
- (1) IN GENERAL.—The Secretary shall enter into a contract with an entity under which such entity carries out a study on the manufacture of essential generic antibiotic drugs and issues a report that includes—
- (A) recommendations about which antibiotics the Secretary should prioritize for purposes of the program under subsection (a), based on factors that include necessity of use, vulnerability to foreign supply chain disruptions, and availability of alternatives; and
- (B) the expected effect of increased domestic manufacturing of drugs on drug costs to consumers.
- (2) AUTHORIZATION.—To carry out this subsection, there is authorized to be appropriated \$2,000,000 for fiscal year 2021, to remain available until September 30, 2022.
- SA 1743. Mr. PADILLA submitted an amendment intended to be proposed to amendment SA 1502 proposed by Mr. SCHUMER to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science